Antibody Ingredients TRIZ Cases

MRG002 antibody drug conjugate overcomes trastuzumab resistance in HER2-expressing cancers via high fucosylation and cleavable linkers.

Segmented antibody fragments block CD155 binding to CD96, inhibiting tumor growth and metastasis.

Segmenting targeting functions into dual-specificity domains enables selective regulatory T cell depletion while sparing effector T cells.

Engineered monoclonal antibodies bind native VCAM-1 on endothelial cells, resolving specificity issues that hinder accurate diagnosis of inflammatory diseases.

Specific anti-CD73 antibodies inhibit enzymatic activity and reduce protein levels, disrupting the immunosuppressive tumor microenvironment.

Segmented biparatopic polypeptides block CXCR2 ligand binding with IC50 under 20nM, treating COPD.

IL-36 pathway inhibitors target upregulated signaling to resolve treatment gaps in hidradenitis suppurativa patients.

Segmenting dimer structures into monomer units connected by flexible linkers improves in vivo stability while maintaining high affinity for PDGFR-β targeting.

Engineered anti-CD45RC antibodies selectively deplete pathogenic T cells, reducing transplant rejection and toxicity compared to corticosteroids.

Humanized monoclonal antibodies with specific CDRs reduce immunogenicity while maintaining high binding affinity to the alpha-folate receptor.

Segmented LILRB2 binding domains resolve stability-versatility trade-offs in multispecific antibody construction.

Combining anti-CSF-1R and anti-PD-L1 antibodies overcomes limited therapeutic options by inhibiting tumor growth and metastasis.

Fully human mAb 91H06 binds B7-H3 on cancer cells, inducing internalization and delivering cytotoxic payloads to inhibit tumor growth.

Blocking P2Y6 receptors in macrophages overcomes resistance to checkpoint inhibitors, reducing M2 polarization and sensitizing resistant pancreatic tumors.

Bispecific antibodies bind CD28 on T cells and PD-L1 on tumor cells to trigger localized immune activation.

Dual-linkage stabilizes antibody-drug conjugates during circulation, reducing off-target toxicity.

Segmented multispecific proteins bridge NK cells and tumors via CD16 and CLEC12A, resolving the trade-off between efficacy and side effects.

Notch3-specific antagonist antibodies treat gamma-secretase inhibitor positive T-cell leukemia that does not respond to anti-Notch1 antagonistic antibody.

Antigen-binding reagents target cancer-specific glycan epitopes on human Periostin to resolve selectivity limits in antibody-based diagnostics.

Combines heat-induced epitope retrieval with protease digestion to expose glypican 3 antigens in formalin-fixed liver tissue sections.

Segmented antibody design prevents NK-NK cross-linking and fratricide while maintaining high avidity binding to CD16A.

Engineered anti-VISTA antibodies with defined CDR sequences modulate immune signaling to treat autoimmune diseases.

Modified linker structures prevent metabolite efflux, extending intracellular residence time and apoptotic action against cancer cells.

Anti-PRLR antibody formulations use excipients to reduce viscosity, preventing phase separation and gelation at high concentrations.

Segmented PRL3-zumab penetrates cancer cells to target intracellular PRL3, overcoming antibody size limits for gastric cancer therapy.

Segmented single domain proteins with specific CDR sequences kill BCMA-expressing cancer cells while reducing systemic toxicity.

Masked anti-CD137 antibodies utilize a masking peptide to block antigen binding during systemic circulation.

Segmented human scFv targets CD99 on Ewing sarcoma cells, resolving drug resistance and immune response trade-offs in conventional therapies.

Measuring the peripheral blood T cell ratio predicts checkpoint inhibitor response without invasive tumor biopsy.

Optimized variable domains achieve 10^-9 to 10^-14 M affinity for MAGE-A4 peptide-MHC, reducing off-target effects in cancer therapy.

Mannosylamino dextran carriers target dermal macrophages, reducing drug resistance and toxicity while improving solubility.

Segmented antibody structures prevent FcγR-mediated clustering to eliminate systemic liver toxicity while enabling localized tumor activation.

CM-918 antibody binds TRA-Podocalyxin to trigger cytotoxicity against cancer cells.

Arginine wash solution removes turbidity and impurities from bound proteins during affinity chromatography, preventing precipitation losses in the elution pool.

Combining tumor-targeted ICOS agonists with T-cell bispecific antibodies overcomes primary resistance in checkpoint blockade therapies.

Humanized monoclonal antibodies bind specifically to the Thomsen-Friedenreich tumor antigen using murine complementarity determining regions within human framework sequences.

Site-specific amino acid substitutions in variable regions of humanized antibodies reduce immunogenicity while maintaining immunomodulatory activity.

Humanized BA-1-3D antibody resolves in vitro to in vivo efficacy gaps via blood-brain barrier penetration.

Dual constant domain Fab antibody fragments extend plasma half-life by reducing renal clearance through stable light and heavy chain pairing.

Site-specific linker design controls drug attachment points on antibodies, resolving heterogeneity issues in therapeutic conjugates.

A bispecific antibody links CD40 and EpCAM binding domains via constant regions to enable targeted antitumor signaling.

Camelid antibodies bind activated protein C to selectively modulate its anticoagulant and cytoprotective functions.

An anti-carboxyethylpyrrole antibody binds CEP derivatives to inhibit angiogenesis.

Anti-CD39 antibodies inhibit CD39 activity to reverse immunosuppression and enhance immune responses against tumors.

Administering anti-PD-1 and anti-CD30 antibodies on specific days improves survival while maintaining safety.

Anti-huGARP antibodies bind human GARP to block active TGF-β release, reducing immunosuppression without systemic toxicity.

Humanized monoclonal antibodies bind specifically to tumor-expressed Nectin-4, reducing off-target binding to normal keratinocytes and minimizing skin toxicity.

Phospholipid bilayer nanocapsules encapsulate nimotuzumab to cross the blood-brain barrier and inhibit glioblastoma proliferation.

Integrin alpha-2 binding agents cross-block antibody binding to reduce tumor growth and angiogenesis.